Liu, Qi, Lingli Hou, Ying Zhao, Hongwei Yang, Zhengying Mo, and Fei Yu. “Comparative Efficacy & Safety of Buparlisib Plus Fulvestrant, Fulvestrant Plus Dalpiciclib, and Ribociclib Plus Letrozole for Postmenopausal, Hormone Receptor-Positive, and HER2-Negative Breast Cancer”. Clinics 78 (May 6, 2023): 100291. Accessed November 13, 2025. https://revistas.usp.br/clinics/article/view/236619.